Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Parkinson’s disease-specific medicines use review

Members of Royal Pharmaceutical Society’s London North West Local Practice Forum (LNW LPF) are working with charity Parkinson’s UK to develop a new service for patients with Parkinson’s disease (PD). The overall aim is to develop a PD-specific medicines use review by designing and trialling it in an initial and follow-up trial.

The idea for the project arose from an LPF event (held in Harrow, Middlesex, in January 2014) in collaboration with the Centre for Pharmacy Postgraduate Education (CPPE). This was addressed by a PD specialist, a representative from Parkinson’s UK and a patient with PD who described problems he faced in everyday life. Interest was expressed among the audience in exploring how pharmacists could better support community-based PD patients.

At a subsequent stakeholder meeting at the UCB Pharma Ltd headquarters in Slough in March 2014, it was agreed that a MUR would be designed and piloted by community pharmacist members of the LNW LPF. The aims of the MUR would be to empower patients and increase their knowledge, achieve better integrated care, improve outcomes, potentially reduce costs to the NHS, identify and resolve problems where possible, and be an informative and fulfilling activity for participating pharmacists. With support from UCB Pharma Ltd, an advisory board was formed consisting a neurologist, specialist PD nurse, two clinical commissioning group lead pharmacists, a GP, a representative from Parkinson’s UK, LNWLPF lead, representatives from UCB and eight community pharmacists (who undertook relevant online training).

The initial meeting in November 2014 led to development of a toolkit containing a Parkinson’s UK information pack, details on how to order support materials for patients and also questionnaire and feedback forms. A patient questionnaire (developed by Parkinson’s UK and Salford Royal NHS Foundation Trust) was to be completed before the MUR to establish a baseline position.

Over two months (March to April 2015) the eight pharmacists conducted 32 PD-specific MURs across eight different pharmacies in North West London and collected data, including pharmacist and patient feedback. Analysis of the data was completed by UCB Pharma Ltd and discussed at a further advisory board meeting.

Patient feedback highlighted problems with non-motor symptoms, both behavioural and physical. Patients also lacked understanding of taking the right dose at the right time, whether medicines should be taken before or after food, frequency of doses, titration problems and how the medicines work. Patients welcomed the opportunity to provide feedback and were pleased to be able to talk to the pharmacist about their concerns and problems.

Around 96% of patients found the MUR useful, 86% felt their understanding of their medicines had improved and 92% thought other people with PD would benefit from this service.

Pharmacist feedback highlighted the need for good communication skills. The participants found the quality time with the patients “immensely satisfying” and they felt empowered having gained knowledge, competence and confidence.

In terms of outcomes from the MURs, four pharmacists identified cases of avoidable harm; six pharmacists reported improved compliance; five pharmacists saw an improvement in patient care; and two pharmacists reported better integrated care with improved communication with GPs.

The positive feedback has prompted a second trial phase with at least 150 MURs being undertaken by 50 pharmacists. Following a presentation at the Pharmacy Show (September 2016) additional pharmacists from outside North West London were recruited for the next phase. Findings from the pilots will be presented to the Pharmaceutical Services Negotiating Committee and NHS England, with a view to a national PD-specific MUR service being launched in 2018.

Stephanie Bancroft

London North West Local Practice Forum lead

Royal Pharmaceutical Society

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201923

Readers' comments (1)

  • as a retired pharmacist whose wife has acute Parkinson's disease
    I am concerned that this process of Parkinson M.U.Rs was discussed two years ago, the clinical trials involving pharmacists followed six months later and only now has a date been set for the implementation of this project has only just begun. At the present rate with the financial cut backs that are now in place the opportunities for such work will be much reduced yet I am convinced the demand for such help from our profession will be significant.
    Can I hope that The Minister Jeremy Hunt and his pharmaceutical lacci Keith Ridge will take note of the point I am making and try in future to seek ways and means of better helping patients such as those with Parkinson's disease instead of reducing pharmaceutical services by these financial cutbacks
    Gerry Green

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and British National Formulary for Children

    BNF and British National Formulary for Children

    Now available as a 1 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and British National Formulary for Children

    BNF and British National Formulary for Children

    Now available as a 2 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.